Man Group plc Takes $2.39 Million Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Man Group plc purchased a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 108,250 shares of the company’s stock, valued at approximately $2,385,000.

Several other large investors have also recently modified their holdings of the business. True Wind Capital Management L.P. raised its stake in shares of Cellebrite DI by 18.2% during the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after acquiring an additional 2,130,386 shares during the last quarter. FMR LLC lifted its holdings in Cellebrite DI by 89.1% in the fourth quarter. FMR LLC now owns 10,621,344 shares of the company’s stock valued at $233,988,000 after buying an additional 5,004,587 shares during the period. Axon Enterprise Inc. bought a new stake in Cellebrite DI during the fourth quarter valued at $198,270,000. Voss Capital LP boosted its position in Cellebrite DI by 1.2% during the fourth quarter. Voss Capital LP now owns 3,240,000 shares of the company’s stock valued at $71,377,000 after acquiring an additional 39,700 shares during the last quarter. Finally, Pertento Partners LLP boosted its position in Cellebrite DI by 26.7% during the fourth quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock valued at $65,547,000 after acquiring an additional 626,373 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on CLBT shares. Needham & Company LLC cut their price target on shares of Cellebrite DI from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Lake Street Capital upped their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. cut their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $22.43.

Cellebrite DI Price Performance

CLBT stock opened at $16.71 on Friday. The stock has a market capitalization of $4.00 billion, a PE ratio of -12.02, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The company’s 50-day moving average is $18.94 and its 200-day moving average is $20.19. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. The company had revenue of $107.55 million for the quarter, compared to analysts’ expectations of $109.36 million. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business’s revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 EPS. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.